This CME-accredited OncoBlast activity delivers key updates on first-line treatment of metastatic urothelial carcinoma (mUC) and muscle-invasive bladder cancer (MIBC), including the latest guidelines and the emerging role of antibody-drug conjugates (ADCs). Through gamified, interactive case scenarios, participants will explore guideline-based care, optimal treatment sequencing, and strategies for managing adverse events. This activity supports the real-world application of evolving evidence in urothelial cancer management.
Course Accreditations
Course Summary
Events Starts | Events Ends |
---|---|
1/1/2025 | 12/31/2025 |
Faculty
Jordan Ciuro (MD)
Dr. Jordan Ciuro is a board-certified medical oncologist specializing in the treatment of genitourinary cancers, including adrenal, bladder, kidney, penile, prostate, and testicular cancers. She practices at the Winship Cancer Institute at Emory Midtown and holds a faculty appointment as Assistant Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. Dr. Ciuro earned her medical degree with honors from the American University of the Caribbean School of Medicine. She completed both her internal medicine residency and hematology/oncology fellowship at Ascension Providence Hospital through Michigan State University, where she served as chief resident and chief fellow in her final years of training. Certified by the American Board of Internal Medicine in Internal Medicine, Medical Oncology, and Hematology, Dr. Ciuro has been practicing since 2022. Her research focuses on investigator-initiated clinical trials that explore geriatric survivorship and healthcare disparities in solid tumors, with the goal of tailoring treatments to reduce toxicity and improve outcomes for vulnerable populations. She is an active member of several professional organizations, including the American College of Physicians, the American Medical Association, and working groups within the ECOG and Caris Precision Oncology Alliance focused on genitourinary cancers. Dr. Ciuro has contributed to scientific literature in journals such as BMJ Case Reports and the Mathews Journal of Case Reports. She is recognized for her patient-centered approach and has received high patient satisfaction scores, reflecting her commitment to compassionate, inclusive care.
Disclosure
- Medical oncologists
- Oncology fellows
- Oncology nurses
- Nurse practitioners
- Physician assistants
- Pharmacists
Target Audience
- Summarize current guideline-recommended first-line therapies and sequencing strategies for advanced urothelial carcinoma.
- Apply a multidisciplinary, patient-centered approach to treatment planning in mUC and MIBC.
- Identify and manage treatment-related adverse events, including those associated with antibody-drug conjugat
Learning Objectives
Upon successful completion of this educational activity, participants will be able to: